<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Japan’s aging population and disease burden are driving decentralized testing, creating opportunities in portable home-care devices, molecular diagnostics and digital integration.Dublin, Sept. 16, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- <a href="https://www.researchandmarkets.com/reports/6262653/japan-ivd-point-care-testing-market-key-company?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=srwpg3&amp;utm_campaign=2350205+-+Japan+IVD+Point-of-Care+Testing+Market+Set+for+Growth+Through+2030%2c+Driven+by+Rapid+Diagnostics+Innovation+and+Expanding+Decentralized+Care&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="Japan IVD Point of Care Testing Market, Key Company Profiles, Market Dynamics and Recent Developments - Forecast to 2030">"Japan IVD Point of Care Testing Market, Key Company Profiles, Market Dynamics and Recent Developments - Forecast to 2030"</a> has been added to ResearchAndMarkets.com's offering. The Japan IVD Point-of-Care (POC) Testing Market is projected to surpass US$700 million by 2030, rising from approximately US$450 million in 2025. Japan remains one of the largest and most technologically advanced point-of-care diagnostics markets in the Asia-Pacific region, supported by its rapidly aging population, growing incidence of chronic and infectious diseases, universal health insurance system and established healthcare infrastructure. Demand for point-of-care testing in Japan continues to increase across hospitals, emergency departments, outpatient clinics, pharmacies, nursing homes and home healthcare environments. The market is benefiting from healthcare providers' focus on faster test results, decentralized diagnostic services and timely clinical decision-making. Blood glucose monitoring, HbA1c testing, blood gas and electrolyte analysis, cardiac biomarkers, urinalysis, infectious disease diagnostics and critical care testing are among the principal areas of adoption. Japan's expanding home healthcare and community-based medical services are creating additional opportunities for portable and connected diagnostic platforms. These systems are increasingly used to support elderly patient care and the long-term management of diabetes, cardiovascular disease, kidney disease and other chronic conditions. Integration with laboratory information systems, electronic medical records and digital health platforms is also strengthening workflow efficiency, data accessibility and clinical coordination. Japan IVD Point-of-Care Testing Market Segment Highlights <ul><li>POC infectious disease testing represents the largest market segment. Growth is supported by seasonal respiratory infections, an aging population and demand for rapid diagnosis in hospitals, emergency departments and outpatient settings. Denka maintains a leading position, while Roche and TAUNS Laboratories are also prominent market participants.</li><li>POC blood gas and electrolyte testing is the second-largest segment, reflecting its importance in intensive care units, operating rooms, emergency medicine and neonatal care. Danaher-Radiometer leads this category, followed by Siemens Healthineers, Techno Medica and Abbott.</li><li>POC urinalysis benefits from the prevalence of chronic kidney disease, diabetes and urinary tract infections, alongside demand for rapid routine screening. Eiken Chemical holds a strong position, with ARKRAY and Siemens Healthineers also competing through advanced platforms and established distribution networks.</li><li>POC chemistry and HbA1c testing is expanding as Japan addresses increasing diabetes prevalence and demand for faster metabolic monitoring. Fujifilm is a leading participant, while ARKRAY, Siemens Healthineers and FUJIFILM Wako maintain significant market positions.</li><li>POC cardiac testing is supported by the growing burden of cardiovascular disease and the need for rapid assessment in emergency and critical care settings. Fukuda Denshi leads through its specialized cardiovascular diagnostics portfolio and extensive domestic hospital network.</li><li>POC critical care testing, including C-reactive protein and procalcitonin assays, remains essential for evaluating severe infections, sepsis and systemic inflammation in acute and intensive care environments.</li></ul> Recent Point-of-Care Diagnostics Developments <ul><li>In July 2026, Roche introduced the cobas HDV test for the detection and quantification of Hepatitis D Virus RNA on the cobas 5800, 6800 and 8800 systems in countries accepting the CE mark. The test is designed to support patient identification and treatment monitoring.</li><li>In April 2025, H.U. Group Holdings and Fujirebio announced that the Global Health Innovative Technology Fund awarded an approximately US$4.5 million, two-year grant to Fluxus. The funding supports development of an ultrasensitive point-of-care urine test for pulmonary and extrapulmonary tuberculosis using single-molecule counting technology.</li><li>In June 2023, Sysmex launched a point-of-care testing system designed to detect antimicrobial susceptibility within 30 minutes. Developed for urinary tract infections, the platform uses microfluidic technology to support responsible antimicrobial use and address antimicrobial resistance.</li></ul> Competitive Landscape Competition in the Japan IVD point-of-care testing market includes established domestic manufacturers and global diagnostics companies. ARKRAY, Fujifilm, Terumo, Denka, Eiken Chemical, Fujirebio, Fukuda Denshi, Sysmex and TAUNS compete alongside Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Danaher-Radiometer, Becton Dickinson and other international suppliers. Market participants continue to invest in molecular diagnostics, connected instruments, assay development, automation and portable testing technologies. Report Coverage The report, "Japan IVD Point of Care (POC) Testing Market-By Segment, Key Company Profiles, Market Dynamics and Recent Developments-Forecast to 2030," provides market size, share and forecast analysis for 2021 through 2030. It evaluates nine principal segments: POC cardiac testing; blood gas and electrolytes; urinalysis; hospital glucose testing connected to laboratory information systems; chemistry and HbA1c; patient monitoring and coagulation; infectious diseases; critical care; and other POC applications. Cardiac testing coverage includes troponin, BNP, pro-BNP and other cardiac biomarkers. Infectious disease analysis includes HIV, sexually transmitted diseases, hepatitis, vector-borne diseases, gastrointestinal infections and respiratory infections. The critical care assessment covers CRP and PCT testing, while the chemistry category includes both general POC chemistry and HbA1c testing. The competitive analysis profiles Denka, Roche, Danaher-Radiometer, D.S. Pharma, Siemens Healthineers, Becton Dickinson, Techno Medica, Eiken Chemical, Fujifilm, FUJIFILM Wako, Fujirebio, Fukuda Denshi, LSI Medience, Sekisui, Abbott, Werfen, Horiba, ARKRAY, Terumo, Nipro, Nihon Kohden, TAUNS, Sysmex-related market developments and other diagnostic technology providers active in Japan. With sustained investment in healthcare digitization, molecular testing, chronic disease management and decentralized care, the Japan IVD point-of-care testing market is positioned for continued expansion through 2030. Rapid infectious disease diagnostics, critical care testing and connected platforms are expected to remain central to future market growth. Key Topics Covered: 1. Executive Summary 2. Research Methodology 2.1 Research Design 2.2 Research Approach 2.3 Data Collection Methods 2.4 Market Assumptions 3. Japan IVD Point of Care (POC) Testing Market and Forecast (2021-2030) 3.1 By Segment - Japan IVD Point of Care (POC) Testing Market Share &amp; Forecast 3.2 By Company - Japan IVD Point of Care (POC) Testing Market Share &amp; Forecast 4. Japan - POC Cardiac Market &amp; Forecast (2021-2030) 4.1 By Company - Japan POC Cardiac Market Revenue &amp; Forecast 4.2 Japan - Troponin Market &amp; Forecast 4.2.1 By Company - Japan Troponin Market Revenue &amp; Forecast 4.3 Japan - BNP Market &amp; Forecast 4.3.1 By Company - Japan BNP Market Revenue &amp; Forecast 4.4 Japan - Pro-BNP Market &amp; Forecast 4.4.1 By Company - Japan Pro-BNP Market Revenue &amp; Forecast 4.5 Japan - Other POC Cardiac Market &amp; Forecast 4.5.1 By Company - Japan Other POC Cardiac Market Revenue &amp; Forecast 5. Japan - POC Bloodgas &amp; Electrolytes Market &amp; Forecast (2021-2030) 5.1 By Company - Japan POC Bloodgas &amp; Electrolytes Market Revenue &amp; Forecast 6. Japan - POC Urinalysis Market &amp; Forecast (2021-2030) 6.1 By Company - Japan POC Urinalysis Market Revenue &amp; Forecast 7. Japan - POC Hospital Glucose (connected to LIS) Market &amp; Forecast (2021-2030) 7.1 By Company - Japan POC Hospital Glucose (connected to LIS) Market Revenue &amp; Forecast 8. Japan - POC Chemistry + HbA1c Market &amp; Forecast (2021-2030) 8.1 By Company - Japan POC Chemistry + HbA1c Market Revenue &amp; Forecast 8.2 Japan - POC Chemistry Market &amp; Forecast 8.2.1 By Company - Japan POC Chemistry Market Revenue &amp; Forecast 8.3 Japan - POC HbA1c Market &amp; Forecast 8.3.1 By Company - Japan POC HbA1c Market Revenue &amp; Forecast 9. Japan - POC Patient Monitoring / Coagulation Market &amp; Forecast (2021-2030) 9.1 By Company - Japan POC Patient Monitoring / Coagulation Market Revenue &amp; Forecast 10. Japan - POC Infectious Diseases Market &amp; Forecast (2021-2030) 10.1 By Company - Japan POC Infectious Diseases Market Revenue &amp; Forecast 10.2 Japan - HIV Market &amp; Forecast 10.2.1 By Company - Japan HIV Market Revenue &amp; Forecast 10.3 Japan - STD Market &amp; Forecast 10.3.1 By Company - Japan STD Market Revenue &amp; Forecast 10.4 Japan - Hepatitis Market &amp; Forecast 10.4.1 By Company - Japan Hepatitis Market Revenue &amp; Forecast 10.5 Japan - VBD Market &amp; Forecast 10.5.1 By Company - Japan VBD Market Revenue &amp; Forecast 10.6 Japan - Gastrointestinal Market &amp; Forecast 10.6.1 By Company - Japan Gastrointestinal Market Revenue &amp; Forecast 10.7 Japan - Respiratory Market &amp; Forecast 10.7.1 By Company - Japan Respiratory Market Revenue &amp; Forecast 11. Japan - POC Critical Care Market &amp; Forecast (2021-2030) 11.1 By Company - Japan POC Critical Care Market Revenue &amp; Forecast 11.2 Japan - CRP Market &amp; Forecast 11.2.1 By Company - Japan CRP Market Revenue &amp; Forecast 11.3 Japan - PCT Market &amp; Forecast 11.3.1 By Company - Japan PCT Market Revenue &amp; Forecast 12. Japan - POC Others Market &amp; Forecast (2021-2030) 12.1 By Company - Japan POC Others Market Revenue &amp; Forecast 12.2 Japan - Pregnancy Market &amp; Forecast 12.2.1 By Company - Japan Pregnancy Market Revenue &amp; Forecast 13. Japan IVD Point of Care (POC) Testing Market - Recent Developments 14. Japan IVD Point of Care (POC) Testing Market - Key Company Profiles, IVD POCT Revenue 14.1 Denka 14.2 Roche 14.3 Danaher - Radiometer 14.4 D.S. Pharma 14.5 Siemens 14.6 Becton Dickinson 14.7 Techno Medica 14.8 EIKEN CHEMICAL 14.9 Fujifilm 14.10 Fujifilm - Wako 14.11 Fujirebio 14.12 Fukuda Denshi 14.13 LSI Medience 14.14 Sekisui 14.15 Abbott 14.16 Werfen - Instrumentation Laboratory 14.17 Horiba ABX - Horiba 14.18 Arkray 14.19 Sanwa 14.20 Terumo 14.21 Nipro 14.22 Nihon Kohden 14.23 Nissui 14.24 Minaris 14.25 Mizuho 14.26 Toyobo 14.27 SD Biosensor 14.28 Nova Biomedical 14.29 Alfresa Pharma 14.30 TAUNS 14.31 Nippon Gene 14.32 Otsuka 15. Japan IVD Point of Care (POC) Testing - Market Dynamics 15.1 Japan IVD Point of Care (POC) Testing Market - Drivers 15.2 Japan IVD Point of Care (POC) Testing Market - Challenges Companies Featured <ul><li>Denka</li><li>Roche</li><li>Danaher - Radiometer</li><li>D.S. Pharma</li><li>Siemens</li><li>Becton Dickinson</li><li>Techno Medica</li><li>EIKEN CHEMICAL</li><li>Fujifilm</li><li>Fujifilm - Wako</li><li>Fujirebio</li><li>Fukuda Denshi</li><li>LSI Medience</li><li>Sekisui</li><li>Abbott</li><li>Werfen - Instrumentation Laboratory</li><li>Horiba ABX - Horiba</li><li>Arkray</li><li>Sanwa</li><li>Terumo</li><li>Nipro</li><li>Nihon Kohden</li><li>Nissui</li><li>Minaris</li><li>Mizuho</li><li>Toyobo</li><li>SD Biosensor</li><li>Nova Biomedical</li><li>Alfresa Pharma</li><li>TAUNS</li><li>Nippon Gene</li><li>Otsuka</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6262653/japan-ivd-point-care-testing-market-key-company?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=srwpg3&amp;utm_campaign=2350205+-+Japan+IVD+Point-of-Care+Testing+Market+Set+for+Growth+Through+2030%2c+Driven+by+Rapid+Diagnostics+Innovation+and+Expanding+Decentralized+Care&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/xmymhn</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/ZWIwMGZhZTYtOGZmMi00YzVlLWEyZjYtNWViOWMwZDRiOTBmLTEwMjY3MzctMjAyNi0wOS0xNi1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

Japan IVD Point-of-Care Testing Market Set for Growth Through 2030, Driven by Rapid Diagnostics Innovation and Expanding Decentralized Care

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn